Washington Trust Advisors’s AstraZeneca AZN Stock Holding History

Washington Trust Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.94K	Buy	+53	New	+$9.97K	﹤0.01%	521
2026 Q1	–	Sell	-45	Closed	-$8.27K	–	690
2025 Q4	$8.27K	Sell	45 -10	-18%	-$1.75K	﹤0.01%	518
2025 Q3	$8.36K	Hold	55	–	–	﹤0.01%	549
2025 Q2	$7.62K	Hold	55	–	–	﹤0.01%	514
2025 Q1	$8.01K	Hold	55	–	–	﹤0.01%	498
2024 Q4	$7.14K	Buy	55 +9	+20%	+$1.26K	﹤0.01%	524
2024 Q3	$7.09K	Sell	46 -134	-74%	-$21.6K	﹤0.01%	528
2024 Q2	$28K	Buy	180 +139	+339%	+$20.9K	﹤0.01%	373
2024 Q1	$5.49K	Hold	41	–	–	﹤0.01%	560
2023 Q4	$5.46K	Buy	+41	New	+$5.33K	﹤0.01%	561
2023 Q2	–	Sell	-197	Closed	-$27.3K	–	673
2023 Q1	$27.3K	Sell	197 -173	-47%	-$23.3K	﹤0.01%	378
2022 Q4	$50.2K	Sell	370 -556	-60%	-$69.7K	0.01%	310
2022 Q3	$102K	Buy	926 +646	+231%	+$82K	0.01%	275
2022 Q2	$37K	Sell	280 -479	-63%	-$62.9K	﹤0.01%	442
2022 Q1	$101K	Sell	759 -125	-14%	-$15K	0.01%	331
2021 Q4	$103K	Buy	+884	New	+$104K	0.01%	357

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Washington Trust Advisors's AZN Position: Q2 2026 in Review

Washington Trust Advisors opened a new position in AstraZeneca (AZN) in Q2 2026: 53 shares worth $9.94K. The stake represents ﹤0.01% of the portfolio and ranks #521 among its holdings. This is a return to the name: Washington Trust Advisors previously reported a position in AZN as recently as Q4 2025.

Washington Trust Advisors first reported a position in AZN in Q4 2021 and has held it in 16 quarters since. The position peaked at $103K in Q4 2021. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Washington Trust Advisors held 53 shares of AstraZeneca worth $9.94K as of Q2 2026.
AstraZeneca was a new Washington Trust Advisors position in Q2 2026.
AstraZeneca made up ﹤0.01% of Washington Trust Advisors's portfolio in Q2 2026, its #521 holding.
Washington Trust Advisors first reported a position in AstraZeneca in Q4 2021 and has held it in 16 quarters since.
Washington Trust Advisors's AstraZeneca position peaked at $103K in Q4 2021.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Washington Trust Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.